Coregulator function: a key to understanding tissue specificity of selective receptor modulators.

Ligands for the nuclear receptor superfamily control many aspects of biology, including development, reproduction, and homeostasis, through regulation of the transcriptional activity of their cognate receptors. Selective receptor modulators (SRMs) are receptor ligands that exhibit agonistic or antagonistic biocharacter in a cell- and tissue context-dependent manner. The prototypical SRM is tamoxifen, which as a selective estrogen receptor modulator, can activate or inhibit estrogen receptor action. SRM-induced alterations in the conformation of the ligand-binding domains of nuclear receptors influence their abilities to interact with other proteins, such as coactivators and corepressors. It has been postulated, therefore, that the relative balance of coactivator and corepressor expression within a given target cell determines the relative agonist vs. antagonist activity of SRMs. However, recent evidence reveals that the cellular environment also plays a critical role in determining SRM biocharacter. Cellular signaling influences the activity and subcellular localization of coactivators and corepressors as well as nuclear receptors, and this contributes to gene-, cell-, and tissue-specific responses to SRM ligands. Increased understanding of the effect of cellular environment on nuclear receptors and their coregulators has the potential to open the field of SRM discovery and research to many members of the nuclear receptor superfamily.

[1]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[2]  B. O’Malley,et al.  Specificity of thyroid hormone receptor subtype and steroid receptor coactivator-1 on thyroid hormone action. , 2003, American journal of physiology. Endocrinology and metabolism.

[3]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[4]  P. Chambon,et al.  Thyroid function in mice with compound heterozygous and homozygous disruptions of SRC-1 and TIF-2 coactivators: evidence for haploinsufficiency. , 2002, Endocrinology.

[5]  J R Wood,et al.  Allosteric modulation of estrogen receptor conformation by different estrogen response elements. , 2001, Molecular endocrinology.

[6]  B. O’Malley,et al.  Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. , 1998, Science.

[7]  C. Allis,et al.  Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter , 2001, Current Biology.

[8]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[9]  R. Goodman,et al.  CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.

[10]  K. Bramlett,et al.  Effects of selective estrogen receptor modulators (SERMs) on coactivator nuclear receptor (NR) box binding to estrogen receptors. , 2002, Molecular genetics and metabolism.

[11]  J. Gustafsson,et al.  A regulatory role for RIP140 in nuclear receptor activation. , 1998, Molecular endocrinology.

[12]  H. Masuya,et al.  Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein-Taybi syndrome. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. O’Malley,et al.  Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[15]  K. Chwalisz,et al.  Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium , 2000, Steroids.

[16]  D. McDonnell,et al.  Evaluation of ligand-dependent changes in AR structure using peptide probes. , 2002, Molecular endocrinology.

[17]  P. Chambon,et al.  The Function of TIF2/GRIP1 in Mouse Reproduction Is Distinct from Those of SRC-1 and p/CIP , 2002, Molecular and Cellular Biology.

[18]  N. Weigel Steroid hormone receptors and their regulation by phosphorylation. , 1996, The Biochemical journal.

[19]  L. Espinosa,et al.  IκBα and p65 Regulate the Cytoplasmic Shuttling of Nuclear Corepressors: Cross-talk between Notch and NFκB Pathways , 2003 .

[20]  B. Katzenellenbogen,et al.  An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Livingston,et al.  Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. , 2000, Genes & development.

[22]  Guillaume Adelmant,et al.  Activation of PPARγ coactivator-1 through transcription factor docking , 1999 .

[23]  Kristen Jepsen,et al.  Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development , 2000, Cell.

[24]  D. Latchman,et al.  Nerve Growth Factor Up-regulates the Transcriptional Activity of CBP through Activation of the p42/p44MAPK Cascade* , 1998, The Journal of Biological Chemistry.

[25]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[26]  K. Grandien,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .

[27]  Kristina Schoonjans,et al.  Thiazolidinediones: an update , 2000, The Lancet.

[28]  D. Robyr,et al.  Nuclear hormone receptor coregulators in action: diversity for shared tasks. , 2000, Molecular endocrinology.

[29]  J. Cidlowski,et al.  The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. , 2002, Molecular endocrinology.

[30]  C. J. Barnes,et al.  A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm , 2002, Nature.

[31]  T. Powles,et al.  Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial , 2004, Breast Cancer Research and Treatment.

[32]  P. Chambon,et al.  The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function , 1988, Cell.

[33]  E. Jensen,et al.  Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Beaudet,et al.  Genetic Ablation of the Steroid Receptor Coactivator-Ubiquitin Ligase, E6-AP, Results in Tissue-Selective Steroid Hormone Resistance and Defects in Reproduction , 2002, Molecular and Cellular Biology.

[35]  B. O’Malley,et al.  Phosphorylation of Steroid Receptor Coactivator-1 , 2000, The Journal of Biological Chemistry.

[36]  O. Hermanson,et al.  Regulation of somatic growth by the p160 coactivator p/CIP. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Harper,et al.  Contrasting Endocrine Activities of cis and trans Isomers in a Series of Substituted Triphenylethylenes , 1966, Nature.

[38]  R. Roeder,et al.  The TRAP/SMCC/Mediator complex and thyroid hormone receptor function , 2001, Trends in Endocrinology & Metabolism.

[39]  Y. Matsuo,et al.  Identification of a Series of Transforming Growth Factor β-Responsive Genes by Retrovirus-Mediated Gene Trap Screening , 2000, Molecular and Cellular Biology.

[40]  S. Tsai,et al.  Cdc25B Functions as a Novel Coactivator for the Steroid Receptors , 2001, Molecular and Cellular Biology.

[41]  Carolyn L. Smith,et al.  Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. , 2003, Molecular endocrinology.

[42]  J. Kurebayashi,et al.  Expression Levels of Estrogen Receptor-α, Estrogen Receptor-β, Coactivators, and Corepressors in Breast Cancer , 2000 .

[43]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[44]  Yuanzheng He,et al.  Modulation of Induction Properties of Glucocorticoid Receptor-Agonist and -Antagonist Complexes by Coactivators Involves Binding to Receptors but Is Independent of Ability of Coactivators to Augment Transactivation* , 2002, The Journal of Biological Chemistry.

[45]  G. Chetrite,et al.  Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. , 1997, Anticancer research.

[46]  Kenneth P Nephew,et al.  The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. , 2003, Molecular endocrinology.

[47]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[48]  M. Imhof,et al.  Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors , 1996, Molecular and cellular biology.

[49]  T. Kouzarides,et al.  Methylation at arginine 17 of histone H3 is linked to gene activation , 2002, EMBO reports.

[50]  Carolyn L. Smith,et al.  Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions , 2002, Steroids.

[51]  C. Glass,et al.  SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. , 1998, Molecular cell.

[52]  Simak Ali,et al.  Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. , 2000, Molecular cell.

[53]  Regulation of glucocorticoid receptor activity by 14--3-3-dependent intracellular relocalization of the corepressor RIP140. , 2001, Molecular endocrinology.

[54]  C. Klinge Estrogen receptor interaction with estrogen response elements. , 2001, Nucleic acids research.

[55]  D. Edwards,et al.  Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. , 1992, The Journal of biological chemistry.

[56]  M. Tsai,et al.  The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily , 1999, Molecular and Cellular Biology.

[57]  R. Weiss,et al.  Mice deficient in the steroid receptor co‐activator 1 (SRC‐1) are resistant to thyroid hormone , 1999, The EMBO journal.

[58]  I. Weinstein,et al.  Inhibition of histone acetyltransferase function of p300 by PKCdelta. , 2002, Biochimica et biophysica acta.

[59]  K. Umesono,et al.  SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[60]  K. Chwalisz,et al.  Selective Progesterone Receptor Modulators (SPRMs) , 2002, Annals of the New York Academy of Sciences.

[61]  P. Chambon,et al.  Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Marc Montminy,et al.  A Transcriptional Switch Mediated by Cofactor Methylation , 2001, Science.

[63]  J. Sumpter,et al.  Differential Effects of Xenoestrogens on Coactivator Recruitment by Estrogen Receptor (ER) α and ERβ* , 2000, The Journal of Biological Chemistry.

[64]  O. Jänne,et al.  PIAS Proteins Modulate Transcription Factors by Functioning as SUMO-1 Ligases , 2002, Molecular and Cellular Biology.

[65]  M. D. Leibowitz,et al.  Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. , 1996, Endocrinology.

[66]  B. O’Malley,et al.  Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ERalpha transcriptional activity and MCF-7 proliferation. , 2002, Molecular endocrinology.

[67]  V. Giguère,et al.  Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. , 1999, Molecular cell.

[68]  R. Renkawitz,et al.  RU486-induced Glucocorticoid Receptor Agonism Is Controlled by the Receptor N Terminus and by Corepressor Binding* , 2002, The Journal of Biological Chemistry.

[69]  D. Agard,et al.  Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[70]  Carolyn L. Smith,et al.  Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. , 2001, Frontiers in bioscience : a journal and virtual library.

[71]  Jiandie D. Lin,et al.  Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. , 2001, Molecular cell.

[72]  S. Ishii,et al.  Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein , 2000, Mechanisms of Development.

[73]  Neil J. McKenna,et al.  Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.

[74]  V. Giguère,et al.  Contribution of steroid receptor coactivator-1 and CREB binding protein in ligand-independent activity of estrogen receptor β , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[75]  J. Gorski,et al.  A ligand-induced conformational change in the estrogen receptor is localized in the steroid binding domain. , 1992, Biochemistry.

[76]  Myles Brown,et al.  Polarity-specific activities of retinoic acid receptors determined by a co-repressor , 1995, Nature.

[77]  Hui Li,et al.  The Receptor-associated Coactivator 3 Activates Transcription through CREB-binding Protein Recruitment and Autoregulation* , 1998, The Journal of Biological Chemistry.

[78]  B. Katzenellenbogen,et al.  Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity* , 2001, The Journal of Biological Chemistry.

[79]  J. Torchia,et al.  Microtubule-Dependent Subcellular Redistribution of the Transcriptional Coactivator p/CIP , 2002, Molecular and Cellular Biology.

[80]  E. Mulder,et al.  Ligand-induced Conformational Alterations of the Androgen Receptor Analyzed by Limited Trypsinization , 1995, The Journal of Biological Chemistry.

[81]  S. Inoue,et al.  Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. , 1997, Biochemical and biophysical research communications.

[82]  B. O’Malley,et al.  Progesterone and Glucocorticoid Receptors Recruit Distinct Coactivator Complexes and Promote Distinct Patterns of Local Chromatin Modification , 2003 .

[83]  P. Chambon,et al.  Differential ligand‐dependent interactions between the AF‐2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. , 1996, The EMBO journal.

[84]  J. Morley,et al.  Biological actions of androgens. , 1987, Endocrine reviews.

[85]  C. Deng,et al.  The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[86]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[87]  L. Sorbera,et al.  ROSIGLITAZONE MALEATE : PROP INNM , 1998 .

[88]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[89]  M. Parker,et al.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Christopher K. Glass,et al.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.

[91]  B. O’Malley,et al.  The 26S Proteasome Is Required for Estrogen Receptor-α and Coactivator Turnover and for Efficient Estrogen Receptor-α Transactivation , 2000 .

[92]  Min Xu,et al.  Steroid-induced Conformational Changes at Ends of the Hormone-binding Domain in the Rat Glucocorticoid Receptor Are Independent of Agonist Versus Antagonist Activity* , 1997, The Journal of Biological Chemistry.

[93]  Bert W O'Malley,et al.  Coordinate Regulation of Transcription and Splicing by Steroid Receptor Coregulators , 2002, Science.

[94]  J. Qin,et al.  Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator Activity by IκB Kinase , 2002, Molecular and Cellular Biology.

[95]  E. Wilson,et al.  Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. , 2002, The Journal of clinical endocrinology and metabolism.

[96]  G. Giannoukos,et al.  New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties. , 2001, Molecular endocrinology.

[97]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[98]  B. O’Malley,et al.  FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. , 2001, Nature cell biology.

[99]  J. Gustafsson,et al.  Functional Differences between the Amino-Terminal Domains of Estrogen Receptors α and β , 2000 .

[100]  B. O’Malley,et al.  Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. , 1993, Molecular endocrinology.

[101]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[102]  L Zhi,et al.  Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone. , 1999, Bioorganic & medicinal chemistry letters.

[103]  G. Mellgren,et al.  The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1. , 2002, Molecular endocrinology.

[104]  Hui Li,et al.  RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[105]  John H. White,et al.  Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. , 2003, Molecular cell.

[106]  R. Turner,et al.  Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[107]  J. Corton,et al.  Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. , 1998, Endocrinology.

[108]  J. Katzenellenbogen,et al.  Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. , 2002, Molecular endocrinology.

[109]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[110]  M. Sporn,et al.  Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). , 2001, Trends in molecular medicine.

[111]  H Grøn,et al.  Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[112]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[113]  A. Wellstein,et al.  A role for TGF-β in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells , 2002, Oncogene.

[114]  N. Webster,et al.  The human estrogen receptor has two independent nonacidic transcriptional activation functions , 1989, Cell.

[115]  W. Baumeister,et al.  The 26S proteasome: a molecular machine designed for controlled proteolysis. , 1999, Annual review of biochemistry.

[116]  D. Fowlkes,et al.  Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β , 1999, Molecular and Cellular Biology.

[117]  R. Turner,et al.  Dose-dependent effects of tamoxifen on long bones in growing rats: influence of ovarian status. , 1991, Endocrinology.

[118]  J. Auwerx,et al.  SRC-1 and TIF2 Control Energy Balance between White and Brown Adipose Tissues , 2002, Cell.

[119]  B. Komm,et al.  Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands. , 2001, Biochemistry.

[120]  J. Davie,et al.  Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. , 1999, Molecular biology of the cell.

[121]  W. Chin,et al.  Identification and Characterization of a Tissue-Specific Coactivator, GT198, That Interacts with the DNA-Binding Domains of Nuclear Receptors , 2022 .

[122]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[123]  K. Nephew,et al.  Expression of Estrogen Receptor Coactivators in the Rat Uterus1 , 2000, Biology of reproduction.

[124]  V. Cavaillès,et al.  Estrogen receptor cofactors expression in breast and endometrial human cancer cells , 1999, Molecular and Cellular Endocrinology.

[125]  C. Glass,et al.  Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. , 1998, Genes & development.

[126]  P. Driggers,et al.  Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes , 2002, Trends in Endocrinology & Metabolism.

[127]  Wolfgang Baumeister,et al.  The Proteasome: Paradigm of a Self-Compartmentalizing Protease , 1998, Cell.

[128]  K. Bramlett,et al.  Ser-884 adjacent to the LXXLL motif of coactivator TRBP defines selectivity for ERs and TRs. , 2002, Molecular endocrinology.

[129]  E. Kalkhoven,et al.  AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors , 1997, Molecular and cellular biology.

[130]  J. Gustafsson,et al.  Differential Recruitment of the Mammalian Mediator Subunit TRAP220 by Estrogen Receptors ERα and ERβ* , 2001, The Journal of Biological Chemistry.

[131]  A. Baniahmad,et al.  The amino terminus of the human AR is target for corepressor action and antihormone agonism. , 2002, Molecular endocrinology.

[132]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[133]  C. Glass,et al.  A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression , 1997, nature.

[134]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[135]  J. Palvimo,et al.  Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[136]  P. Chambon,et al.  Steroid hormone receptors compete for factors that mediate their enhancer function , 1989, Cell.

[137]  G. Chetrite,et al.  The selective estrogen enzyme modulator (SEEM) in breast cancer , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[138]  H. Seo,et al.  Steroid receptor coactivator-1 deficiency causes variable alterations in the modulation of T(3)-regulated transcription of genes in vivo. , 2002, Endocrinology.

[139]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[140]  S. Cowley,et al.  Estrogen Receptors α and β Form Heterodimers on DNA* , 1997, The Journal of Biological Chemistry.

[141]  D. McDonnell,et al.  The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.

[142]  P Chambon,et al.  Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. , 1990, The EMBO journal.

[143]  A. Nordheim,et al.  MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP. , 1996, Biochemical and biophysical research communications.

[144]  S. Cl,et al.  Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. , 2001 .

[145]  W. Chin,et al.  Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[146]  Bruce A. Johnson,et al.  Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.

[147]  S. Nemoto,et al.  Identification of a specific molecular repressor of the peroxisome proliferator-activated receptor gamma Coactivator-1 alpha (PGC-1alpha). , 2002, The Journal of biological chemistry.

[148]  D. McDonnell,et al.  Development of peptide antagonists that target estrogen receptor–cofactor interactions , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[149]  C. Lange,et al.  Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[150]  B. O’Malley,et al.  The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor , 1992, Cell.

[151]  J. Gustafsson,et al.  Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. , 1998, Molecular pharmacology.

[152]  D. McDonnell,et al.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.

[153]  B. Katzenellenbogen,et al.  Transcription Activation by the Human Estrogen Receptor Subtypeβ (ERβ) Studied with ERβ and ERα Receptor Chimeras* *This work was supported by NIH Grants CA-18119 and CA-60514 (to B.S.K.). , 1998, Endocrinology.

[154]  S. Jentsch,et al.  Ubiquitin and proteasomes: Sumo, ubiquitin's mysterious cousin , 2001, Nature Reviews Molecular Cell Biology.

[155]  J. Edwards,et al.  New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. , 1998, Bioorganic & medicinal chemistry letters.

[156]  S. Simons,et al.  Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression. , 1999, Molecular endocrinology.

[157]  D. Fowlkes,et al.  Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. , 1999, Molecular and cellular biology.

[158]  R. Darnell,et al.  Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. , 2000, Molecular cell.

[159]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[160]  L. Murphy,et al.  Altered expression of estrogen receptor coregulators during human breast tumorigenesis. , 2000, Cancer research.

[161]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[162]  M. Guenther,et al.  Proteasomal regulation of nuclear receptor corepressor-mediated repression. , 1998, Genes & development.

[163]  D. DeFranco,et al.  Glucocorticoid receptors in hippocampal neurons that do not engage proteasomes escape from hormone-dependent down-regulation but maintain transactivation activity. , 2002, Molecular endocrinology.

[164]  J. Gustafsson,et al.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.

[165]  D. Thompson,et al.  Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. , 2000, Endocrinology.

[166]  B. O’Malley,et al.  Reproductive functions of progesterone receptors. , 2002, Recent progress in hormone research.

[167]  R. Russell,et al.  A dynamic structural model for estrogen receptor-alpha activation by ligands, emphasizing the role of interactions between distant A and E domains. , 2002, Molecular cell.

[168]  Zhi-Ren Liu p68 RNA Helicase Is an Essential Human Splicing Factor That Acts at the U1 snRNA-5′ Splice Site Duplex , 2002, Molecular and Cellular Biology.

[169]  O. Hermanson,et al.  Nuclear receptor coregulators: multiple modes of modification , 2002, Trends in Endocrinology & Metabolism.

[170]  R. Evans,et al.  Activation and repression by nuclear hormone receptors: hormone modulates an equilibrium between active and repressive states , 1996, Molecular and cellular biology.

[171]  M. Southey,et al.  Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. , 2001, Cancer research.

[172]  R. Evans,et al.  Regulation of Hormone-Induced Histone Hyperacetylation and Gene Activation via Acetylation of an Acetylase , 1999, Cell.

[173]  Donald P. McDonnell,et al.  The Opposing Transcriptional Activities of the Two Isoforms of the Human Progesterone Receptor Are Due to Differential Cofactor Binding , 2000, Molecular and Cellular Biology.

[174]  Y. Niu,et al.  Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer , 2002, British Journal of Cancer.

[175]  J. C. Ghosh,et al.  Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT* , 2003, The Journal of Biological Chemistry.

[176]  P. Jones,et al.  Activation of Transcription by Estrogen Receptor α and β Is Cell Type- and Promoter-dependent* , 1999, The Journal of Biological Chemistry.

[177]  D. Metzger,et al.  Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. , 1999, Molecular and cellular biology.

[178]  Carolyn L. Smith,et al.  Mechanistic Differences in the Activation of Estrogen Receptor-α (ERα)- and ERβ-dependent Gene Expression by cAMP Signaling Pathway(s)* , 2003, The Journal of Biological Chemistry.

[179]  M. Nakane,et al.  A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. , 2003, Molecular endocrinology.

[180]  O. Jänne,et al.  The Nuclear Receptor Interaction Domain of GRIP1 Is Modulated by Covalent Attachment of SUMO-1* , 2002, The Journal of Biological Chemistry.

[181]  A. Balen,et al.  Polycystic ovary syndrome and cancer. , 2001, Human reproduction update.

[182]  N. Weigel,et al.  8-Bromo-Cyclic AMP Induces Phosphorylation of Two Sites in SRC-1 That Facilitate Ligand-Independent Activation of the Chicken Progesterone Receptor and Are Critical for Functional Cooperation between SRC-1 and CREB Binding Protein , 2000, Molecular and Cellular Biology.

[183]  S. Schreiber,et al.  Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase , 1997, Cell.

[184]  J. Shabanowitz,et al.  Androgen Receptor Phosphorylation , 2002, The Journal of Biological Chemistry.

[185]  M. Parker,et al.  Steroid and related receptors. , 1993, Current opinion in cell biology.

[186]  C. Glass,et al.  Molecular determinants of nuclear receptor-corepressor interaction. , 1999, Genes & development.

[187]  M. Privalsky,et al.  The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export , 2000, Molecular and Cellular Biology.

[188]  Jeffrey A. Lefstin,et al.  Allosteric effects of DNA on transcriptional regulators , 1998, Nature.

[189]  B. O’Malley,et al.  Sequential recruitment of steroid receptor coactivator-1 (SRC-1) and p300 enhances progesterone receptor-dependent initiation and reinitiation of transcription from chromatin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[190]  M. Pazin,et al.  What's Up and Down with Histone Deacetylation and Transcription? , 1997, Cell.

[191]  J. Lees,et al.  Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.

[192]  Jason D. Hoeksema,et al.  Analysis of Estrogen Receptor Interaction with a Repressor of Estrogen Receptor Activity (REA) and the Regulation of Estrogen Receptor Transcriptional Activity by REA* , 2000, The Journal of Biological Chemistry.

[193]  J B Lawrence,et al.  Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. , 1994, Genes & development.

[194]  F. Saatcioglu,et al.  DNA Binding-independent Transcriptional Activation by the Androgen Receptor through Triggering of Coactivators* , 2001, The Journal of Biological Chemistry.

[195]  Hui Li,et al.  The Human Homologue of the Yeast DNA Repair and TFIIH Regulator MMS19 Is an AF-1-specific Coactivator of Estrogen Receptor* , 2001, The Journal of Biological Chemistry.

[196]  J. Font de Mora,et al.  AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.

[197]  J. Auwerx,et al.  A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. , 2001, Molecular cell.

[198]  W. Wahli,et al.  A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. , 2002, Molecular endocrinology.

[199]  David Newsome,et al.  Gene Dosage–Dependent Embryonic Development and Proliferation Defects in Mice Lacking the Transcriptional Integrator p300 , 1998, Cell.

[200]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[201]  Anne E Carpenter,et al.  Regulation of Nuclear Receptor Transcriptional Activity by a Novel DEAD Box RNA Helicase (DP97)* , 2003, The Journal of Biological Chemistry.

[202]  Yang Shi,et al.  Stimulation of p300-mediated Transcription by the Kinase MEKK1* , 2001, The Journal of Biological Chemistry.

[203]  J. Gustafsson,et al.  Inactivation of the Nuclear Receptor Coactivator RAP250 in Mice Results in Placental Vascular Dysfunction , 2003, Molecular and Cellular Biology.

[204]  J. Ellenberg,et al.  Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. , 2003, Molecular cell.

[205]  N. Weigel,et al.  The Nuclear Corepressors NCoR and SMRT Are Key Regulators of Both Ligand- and 8-Bromo-Cyclic AMP-Dependent Transcriptional Activity of the Human Progesterone Receptor , 1998, Molecular and Cellular Biology.

[206]  Carolyn L. Smith,et al.  Subnuclear Trafficking of Estrogen Receptor-α and Steroid Receptor Coactivator-1 , 2000 .

[207]  J. Cidlowski,et al.  Molecular identification and characterization of a and b forms of the glucocorticoid receptor. , 2001, Molecular endocrinology.

[208]  A. Negro-Vilar Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. , 1999, The Journal of clinical endocrinology and metabolism.

[209]  M. Erdos,et al.  p300 Modulates the BRCA1 inhibition of estrogen receptor activity. , 2002, Cancer research.

[210]  B. Katzenellenbogen,et al.  Estrogen receptor activation function 1 works by binding p160 coactivator proteins. , 1998, Molecular endocrinology.

[211]  P. Puigserver,et al.  Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. , 2000, Molecular cell.

[212]  Wenbo Yang,et al.  Regulation of Transcription by AMP-activated Protein Kinase , 2001, The Journal of Biological Chemistry.

[213]  S. Robinson,et al.  Species-specific pharmacology of antiestrogens: role of metabolism. , 1987, Federation proceedings.

[214]  M. Parker,et al.  Interaction of proteins with transcriptionally active estrogen receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[215]  I. Bièche,et al.  Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[216]  S. Kato,et al.  Retracted: A subfamily of RNA‐binding DEAD‐box proteins acts as an estrogen receptor α coactivator through the N‐terminal activation domain (AF‐1) with an RNA coactivator, SRA , 2001 .

[217]  Nicholas Bruchovsky,et al.  Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[218]  R. Haché,et al.  Attenuation of glucocorticoid signaling through targeted degradation of p300 via the 26S proteasome pathway. , 2002, Molecular endocrinology.

[219]  B. O’Malley,et al.  Ligand-dependent conformational changes in thyroid hormone and retinoic acid receptors are potentially enhanced by heterodimerization with retinoic X receptor , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[220]  F. Miralles,et al.  Characterization of the proximal estrogen-responsive element of human cathepsin D gene. , 1994, Molecular endocrinology.

[221]  J. Lindgren,et al.  Effects of anti-estrogens on bone in castrated and intact female rats , 1987, Breast Cancer Research and Treatment.

[222]  D. Lannigan Estrogen receptor phosphorylation , 2003, Steroids.

[223]  L. Freedman,et al.  Reciprocal Recruitment of DRIP/Mediator and p160 Coactivator Complexes in Vivo by Estrogen Receptor* , 2002, The Journal of Biological Chemistry.

[224]  M. Garabedian,et al.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.

[225]  B. Deroo,et al.  Proteasome Inhibitors Reduce Luciferase and β-Galactosidase Activity in Tissue Culture Cells* , 2002, The Journal of Biological Chemistry.

[226]  D. McDonnell,et al.  A negative coregulator for the human ER. , 2002, Molecular endocrinology.

[227]  B. O’Malley,et al.  The tau 4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing , 1995, Molecular and cellular biology.

[228]  A. Nardulli,et al.  Estrogen Response Elements Alter Coactivator Recruitment through Allosteric Modulation of Estrogen Receptor β Conformation* , 2001, The Journal of Biological Chemistry.

[229]  J. Wood,et al.  Interaction of estrogen receptors α and β with estrogen response elements , 2001, Molecular and Cellular Endocrinology.

[230]  S. Davis,et al.  Androgen replacement in women: a commentary. , 1999, The Journal of clinical endocrinology and metabolism.

[231]  K. Nephew,et al.  The activating enzyme of NEDD8 inhibits steroid receptor function. , 2002, Molecular endocrinology.

[232]  K. Korach,et al.  Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. , 2002, Molecular endocrinology.

[233]  S. Misiti,et al.  Expression and hormonal regulation of coactivator and corepressor genes. , 1998, Endocrinology.

[234]  Mark Ptashne,et al.  Negative effect of the transcriptional activator GAL4 , 1988, Nature.

[235]  Chawnshang Chang,et al.  Proteasome Activity Is Required for Androgen Receptor Transcriptional Activity via Regulation of Androgen Receptor Nuclear Translocation and Interaction with Coregulators in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[236]  P. Chambon,et al.  TFIIH Interacts with the Retinoic Acid Receptor γ and Phosphorylates Its AF-1-activating Domain through cdk7* , 2000, The Journal of Biological Chemistry.

[237]  J. Thomsen,et al.  Mechanisms of estrogen action. , 2001, Physiological reviews.

[238]  I. Todd,et al.  A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.

[239]  A. Takeshita,et al.  Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. , 1996, Endocrinology.

[240]  J. Pike,et al.  Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.

[241]  S. Cowley,et al.  A comparison of transcriptional activation by ERα and ERβ , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[242]  E. Yeh,et al.  Ubiquitin-like proteins: new wines in new bottles. , 2000, Gene.

[243]  J. Thomsen,et al.  DAX-1 Functions as an LXXLL-containing Corepressor for Activated Estrogen Receptors* , 2000, The Journal of Biological Chemistry.

[244]  D. Trouche,et al.  Control of CBP co‐activating activity by arginine methylation , 2002, The EMBO journal.

[245]  D. DeFranco,et al.  Proteasomal Inhibition Enhances Glucocorticoid Receptor Transactivation and Alters Its Subnuclear Trafficking , 2002, Molecular and Cellular Biology.

[246]  Xiaodong Cheng,et al.  Synergy among Nuclear Receptor Coactivators: Selective Requirement for Protein Methyltransferase and Acetyltransferase Activities , 2002, Molecular and Cellular Biology.

[247]  Neil J McKenna,et al.  A Steroid Receptor Coactivator, SRA, Functions as an RNA and Is Present in an SRC-1 Complex , 1999, Cell.

[248]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[249]  R. Shiu,et al.  Mechanism of estrogen activation of c-myc oncogene expression. , 1992, Oncogene.

[250]  D. Aswad,et al.  Regulation of transcription by a protein methyltransferase. , 1999, Science.

[251]  E. Treuter,et al.  Cloning and Characterization of RAP250, a Novel Nuclear Receptor Coactivator* , 2000, The Journal of Biological Chemistry.

[252]  Simak Ali,et al.  Human Estrogen Receptor β Binds DNA in a Manner Similar to and Dimerizes with Estrogen Receptor α* , 1997, The Journal of Biological Chemistry.

[253]  Johan Malm,et al.  Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[254]  Neil J McKenna,et al.  Hierarchical Affinities and a Bipartite Interaction Model for Estrogen Receptor Isoforms and Full-length Steroid Receptor Coactivator (SRC/p160) Family Members* , 2003, The Journal of Biological Chemistry.

[255]  P. Giangrande,et al.  Mapping and Characterization of the Functional Domains Responsible for the Differential Activity of the A and B Isoforms of the Human Progesterone Receptor* , 1997, The Journal of Biological Chemistry.

[256]  D. Latchman,et al.  Nerve growth factor up-regulates the transcriptional activity of CBP through activation of the p42/p44(MAPK) cascade. , 1998, The Journal of biological chemistry.

[257]  M. Parker,et al.  The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. , 1993, Journal of cell science.

[258]  T. Kitamoto,et al.  p300 Mediates Functional Synergism between AF-1 and AF-2 of Estrogen Receptor α and β by Interacting Directly with the N-terminal A/B Domains* , 2000, The Journal of Biological Chemistry.

[259]  S. Safe Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. , 2001, Vitamins and hormones.

[260]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[261]  J. Williamson,et al.  THE INDUCTION OF OVULATION BY TAMOXIFEN , 1973, The Journal of obstetrics and gynaecology of the British Commonwealth.

[262]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[263]  M. Stallcup,et al.  Synergistic Enhancement of Nuclear Receptor Function by p160 Coactivators and Two Coactivators with Protein Methyltransferase Activities* , 2001, The Journal of Biological Chemistry.

[264]  Sandip K. Mishra,et al.  Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor , 2000, Nature Cell Biology.

[265]  B. O’Malley,et al.  Acute Disruption of Select Steroid Receptor Coactivators Prevents Reproductive Behavior in Rats and Unmasks Genetic Adaptation in Knockout Mice EDE , 2002 .

[266]  D. Forrest,et al.  Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice. , 2002, Molecular endocrinology.

[267]  D P McDonnell,et al.  Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. , 1993, Molecular endocrinology.

[268]  F. Melchior,et al.  SUMO--nonclassical ubiquitin. , 2000, Annual review of cell and developmental biology.

[269]  S. Yeh,et al.  Suppression of Androgen Receptor Transactivation by Pyk2 via Interaction and Phosphorylation of the ARA55 Coregulator* , 2002, The Journal of Biological Chemistry.

[270]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[271]  R. Evans,et al.  Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. , 2001, Genes & development.

[272]  J. Yates,et al.  A novel estrogen receptor α-associated protein, template-activating factor iβ, inhibits acetylation and transactivation , 2003 .

[273]  Shih-Ming Huang,et al.  Synergistic, p160 Coactivator-dependent Enhancement of Estrogen Receptor Function by CARM1 and p300* , 2000, The Journal of Biological Chemistry.

[274]  J. Cidlowski,et al.  Proteasome-mediated Glucocorticoid Receptor Degradation Restricts Transcriptional Signaling by Glucocorticoids* , 2001, The Journal of Biological Chemistry.

[275]  K. Chwalisz,et al.  Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. , 2002, Annals of the New York Academy of Sciences.

[276]  H. Pols,et al.  Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. , 1999, Biochemical and biophysical research communications.

[277]  T. Shiozawa,et al.  Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium. , 2003, The Journal of clinical endocrinology and metabolism.

[278]  B. O’Malley,et al.  The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. , 1987, Biochemical and biophysical research communications.

[279]  Z. Nawaz,et al.  Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. , 2003, Molecular endocrinology.

[280]  D. McDonnell,et al.  RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. , 1994, The Journal of biological chemistry.

[281]  A. Kralli,et al.  A Tissue-Specific Coactivator of Steroid Receptors, Identified in a Functional Genetic Screen , 2000, Molecular and Cellular Biology.

[282]  N. Spinner,et al.  Unique forms of human and mouse nuclear receptor corepressor SMRT. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[283]  S. Windahl,et al.  The nuclear-receptor interacting protein (RIP) 140 binds to the human glucocorticoid receptor and modulates hormone-dependent transactivation , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[284]  M Carlquist,et al.  Structural insights into the mode of action of a pure antiestrogen. , 2001, Structure.

[285]  V. Jordan Biochemical pharmacology of antiestrogen action. , 1984, Pharmacological reviews.

[286]  J. McNally,et al.  The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. , 2000, Science.

[287]  S. Fawell,et al.  Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[288]  J. Gustafsson,et al.  Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context. , 2002, Molecular endocrinology.

[289]  G. Martin,et al.  Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. , 1994, Science.

[290]  W. Chin,et al.  Identification and Characterization of RRM-containing Coactivator Activator (CoAA) as TRBP-interacting Protein, and Its Splice Variant as a Coactivator Modulator (CoAM)* , 2001, The Journal of Biological Chemistry.

[291]  P. Yen,et al.  Physiological and molecular basis of thyroid hormone action. , 2001, Physiological reviews.

[292]  Paul,et al.  Advances in Brief In Breast Cancer , Amplification of the Steroid Receptor Coactivator Gene AIB 1 Is Correlated with Estrogen and Progesterone Receptor Positivity ’ , 2005 .

[293]  M. Erdos,et al.  Role of direct interaction in BRCA1 inhibition of estrogen receptor activity , 2001, Oncogene.

[294]  P. Meltzer,et al.  A Nuclear Factor, ASC-2, as a Cancer-amplified Transcriptional Coactivator Essential for Ligand-dependent Transactivation by Nuclear Receptors in Vivo * , 1999, The Journal of Biological Chemistry.

[295]  M. Tzukerman,et al.  Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.

[296]  P. Chambon,et al.  Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.

[297]  Helmut Dotzlaw,et al.  Expression of the steroid receptor RNA activator in human breast tumors. , 1999, Cancer research.

[298]  M. Parker,et al.  Molecular Determinants of the Estrogen Receptor-Coactivator Interface , 1999, Molecular and Cellular Biology.

[299]  Russell Hilf,et al.  The Effects of Estrogen-Responsive Element- and Ligand-Induced Structural Changes on the Recruitment of Cofactors and Transcriptional Responses by ERα and ERβ , 2002 .

[300]  D. Kressler,et al.  Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[301]  B. Spiegelman,et al.  Degradation of the Peroxisome Proliferator-activated Receptor γ Is Linked to Ligand-dependent Activation* , 2000, The Journal of Biological Chemistry.

[302]  B. Katzenellenbogen,et al.  Conformational Changes and Coactivator Recruitment by Novel Ligands for Estrogen Receptor-α and Estrogen Receptor-β: Correlations with Biological Character and Distinct Differences among SRC Coactivator Family Members. , 2000, Endocrinology.

[303]  P. Meltzer,et al.  In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[304]  S. Robinson,et al.  Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. , 1988, Cancer research.

[305]  A. Kornblihtt,et al.  Antagonistic effects of T‐Ag and VP16 reveal a role for RNA pol II elongation on alternative splicing , 2001, The EMBO journal.

[306]  R. Schüle,et al.  FHL2, a novel tissue‐specific coactivator of the androgen receptor , 2000, The EMBO journal.

[307]  P. Driggers,et al.  Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling , 2002, Trends in Endocrinology & Metabolism.

[308]  V. Ogryzko,et al.  p300 and p300/cAMP-response Element-binding Protein-associated Factor Acetylate the Androgen Receptor at Sites Governing Hormone-dependent Transactivation* , 2000, The Journal of Biological Chemistry.

[309]  K. Bramlett,et al.  Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. , 2001, Molecular endocrinology.

[310]  E. Baracat,et al.  Estrogen activity and novel tissue selectivity of delta8,9-dehydroestrone sulfate in postmenopausal women. , 1999, The Journal of clinical endocrinology and metabolism.

[311]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[312]  D. McDonnell,et al.  Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. , 2002, Molecular endocrinology.

[313]  D. Fowlkes,et al.  Peptide antagonists of the human estrogen receptor. , 1999, Science.

[314]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[315]  E. Milgrom,et al.  Sumoylation of the Progesterone Receptor and of the Steroid Receptor Coactivator SRC-1* , 2003, The Journal of Biological Chemistry.

[316]  K.,et al.  A new derivative of triphenylethylene: effect on implantation and mode of action in rats. , 1967, Journal of reproduction and fertility.

[317]  D. Livingston,et al.  Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300 , 2003, Science.

[318]  J. Gustafsson,et al.  Differential Response of Estrogen Receptor a and Estrogen Receptor b to Partial Estrogen Agonists/Antagonists , 1998 .

[319]  V. Jordan The strategic use of antiestrogens to control the development and growth of breast cancer. , 1992, Cancer.

[320]  C. Turck,et al.  Growth Factors Signal to Steroid Receptors through Mitogen-activated Protein Kinase Regulation of p160 Coactivator Activity* , 2001, The Journal of Biological Chemistry.

[321]  B. O’Malley,et al.  Regulation of Alternative Splicing by the ATP-Dependent DEAD-Box RNA Helicase p72 , 2002, Molecular and Cellular Biology.

[322]  O. Jänne,et al.  Involvement of Proteasome in the Dynamic Assembly of the Androgen Receptor Transcription Complex* , 2002, The Journal of Biological Chemistry.

[323]  H. Kloosterboer Tibolone: a steroid with a tissue-specific mode of action , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[324]  H. Kloosterboer,et al.  Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (±progestogen) treatments , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[325]  Gregor Eichele,et al.  Mutation of the Angelman Ubiquitin Ligase in Mice Causes Increased Cytoplasmic p53 and Deficits of Contextual Learning and Long-Term Potentiation , 1998, Neuron.

[326]  Werner Rath,et al.  Progestins, progesterone receptor modulators, and progesterone antagonists change VEGF release of endometrial cells in culture , 2000, Steroids.

[327]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[328]  Y. Kong,et al.  Dynamic inhibition of nuclear receptor activation by corepressor binding. , 2003, Molecular endocrinology.

[329]  D. Bowtell,et al.  Isolation and characterisation of murine homologues of the Drosophila seven in absentia gene (sina). , 1993, Development.

[330]  K. Horwitz,et al.  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. , 1997, Molecular endocrinology.

[331]  H L Pearce,et al.  Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. , 2001, Cancer research.

[332]  K.,et al.  Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[333]  W. Chin,et al.  Different DNA Elements Can Modulate the Conformation of Thyroid Hormone Receptor Heterodimer and Its Transcriptional Activity* , 1996, The Journal of Biological Chemistry.

[334]  Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. , 1993 .

[335]  D. Kressler,et al.  The PGC-1-related Protein PERC Is a Selective Coactivator of Estrogen Receptor α* , 2002, The Journal of Biological Chemistry.

[336]  I. Rosewell,et al.  The nuclear receptor co-repressor Nrip1 (RIP140) is essential for female fertility , 2000, Nature Medicine.